Nuvectis Pharma to Participate in the Maxim Growth Summit 2026
Globe Newswire•09/10/2026•08:00 ET
0
Key Highlights
- ➤Nuvectis management to participate in Maxim Growth Summit 2026 on October 14
- ➤Ron Bentsur scheduled to present at Immunology & Inflammation Therapies panel
- ➤Ciprocopan recently approved in China for previously untreated PNH patients
- ➤Nuvectis pipeline includes oncology candidates NXP200 and NXP900
Expert Statements
Ron Bentsur, Chairman, Chief Executive Officer and President of Nuvectis Pharma
“members of senior management will participate in the Maxim Growth Summit 2026 on Wednesday, October 14, 2026 in New York”
Fort Lee, NJ, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today announced that members of senior management will participate in the Maxim Growth Summit 2026 on Wednesday, October 14, 2026 in New York.
A webcast of the panel discussion will be available in the Investors section of Nuvectis’ website at www.nuvectis.com.
Get started
Create a free account to read the full story.